ENLV
NASD Enlivex Ltd.$0.2600 ↓ -0.0170 (-6.14%) Trading Down from the previous close of $0.2770
- YTD change
- -97.54%
- vs 20-day SMA
- -56.03%
- vs 200-day SMA
- -97.31%
Price ranges
Price & Performance
-0.67 (-70.83%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $673.5000
- ENLV is down 98% since the beginning of the year
- ENLV is down 99% over the past 12 months
- ENLV is down 73% over the past 1 month
- 0% of all ENLV investors are betting against ENLV
ENLV reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -76.4%.
- Previous minute
- +$0.0047
- Last hour
- +$0.0096
- Last 5 days
- -38.49%
- vs 8-day SMA
- -32.43%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.